European office withdraws Nexium patent

Dec 21, 2006

The European Patent Office, answering a generic drug maker's challenge, withdrew a patent on Britain-based AstraZeneca PLC's heartburn treatment, Nexium.

AstraZeneca officials said they were disappointed with the patent office's decision, but had other patents and intellectual property measures that protected the drug in Europe, the Wall Street Journal said. The ruling involved the drug's chemical composition. The patent was due to expire in 2014.

The generic drug maker Ratiopharm International GmbH of Germany challenged the patent, which led to the EPO's decision. Ratiopharm has not indicated its plans regarding a generic form of Nexium.

Generic drug makers are challenging Nexium's patents in the United States.

AstraZeneca said Nexium's $4.6 billion in worldwide sales accounted for about a fifth of the company's third-quarter revenue.

Copyright 2006 by United Press International

Explore further: Anti-cholinergic drugs impair physical function in elderly patients

add to favorites email to friend print save as pdf

Related Stories

India denies revoking Roche patent, says it lapsed

Aug 06, 2013

India on Monday denied revoking additional patents related to Roche Holding's breast cancer drug Herceptin, saying the Swiss giant failed to follow legal procedures so the applications lapsed.

Walgreen 3Q profit jumps but misses estimates

Jun 25, 2013

Walgreen Co.'s fiscal third quarter earnings jumped 16 percent, but its shares plunged Tuesday as investors fretted over sluggish sales outside the drugstore chain's pharmacies and other troubling trends.

Research shows moves to ban pay-to-delay deals are justified

Jun 18, 2013

Controversial deals that delay generic versions of drugs coming onto the market can lead to consumers paying significantly more for some treatments, according to new research by an academic from the University of East Anglia ...

Actavis buying Warner Chilcott in $8.5B deal

May 20, 2013

Actavis is buying Warner Chilcott in an all-stock deal valued at about $8.5 billion that would create the third-biggest specialty pharmaceutical company in the U.S. market.

Recommended for you

FDA to start regulating lab-developed tests

Jul 31, 2014

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments : 0